PI 3-Kinase Signaling Pathways in Disease
joint with Integrating Metabolism and Tumor Biology
Organizer(s): Lori Friedman, David A. Fruman and Phillip T. HawkinsDate: January 13 - 18, 2015
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
The PI3K-Akt-mTOR signaling pathway is one of the primary mechanisms for controlling cell growth, survival and motility in response to intracellular signaling and extracellular cues. Genetic events resulting in inappropriate activation of this pathway are common in many cancers and, as a result, are a focus of both basic cancer research and drug discovery efforts in oncology. The PI3K-Akt-mTOR network also controls diverse aspects of inflammation and adaptive immunity. Although originally modeled as an independent and linear signaling cascade, today it is evident that the PI3K pathway also functions as a central hub for cross-talk in both vertical as well as reciprocal feedback regulation with other important signaling pathways. How metabolic pathways are regulated to meet the unique needs of tumor cells and activated lymphocytes is a fertile area of study, with mounting evidence that metabolic regulation is intimately linked with the signal transduction pathways that control cell growth and proliferation. One of the exciting advances in the field is the development of new inhibitors against this pathway. However, the rationale for inhibiting individual or multiple isoforms of PI3K/Akt/mTOR signaling remains a subject of intense debate. This Keystone Symposia meeting aims to bring together scientists and clinicians from academia and industry to discuss the opportunities and liabilities of targeting the PI3K- and related pathways in disease, drawing on human pathophysiology and genetics, preclinical models and clinical data on PI3K pathway inhibitors. The joint meeting on “Integrating Metabolism and Tumor Biology” will enhance opportunities for interdisciplinary interactions.
Scholarship Deadline: September 24 2014
Discounted Abstract Deadline: September 24 2014
Abstract Deadline: October 16 2014
Discounted Registration Deadline: November 13 2014
We gratefully acknowledge additional support for this conference from:
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:
Novartis Pharma AG
We gratefully acknowledge the generous grant for this conference provided by:National Cancer Institute (NCI)
Grant No. 1R13CA189371-01
Funding for this conference was made possible (in part) by 1R13CA189371-01 from the National Cancer Institute. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.